Preferred Label : crisaborole;

MeSH note : NSAID, Dermatologic Agent; structure in first source;

CISMeF synonym : 5-(4-cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole; AN2728;

MeSH hyponym : AN-2728;

Is substance : O;

UNII : Q2R47HGR7P;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/staquis
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
crisaborole
crisaborole
drug approval
europe
adult
child
adolescent
dermatitis, atopic
administration, cutaneous
ointments
crisaborole
product surveillance, postmarketing
drug interactions
breast feeding
pregnancy
phosphodiesterase 4 inhibitors
anti-inflammatory agents, non-steroidal
anti-inflammatory agents, non-steroidal
cytokines
drug evaluation, preclinical
Product containing precisely crisaborole 20 milligram/1 gram conventional release cutaneous ointment (clinical drug)
boron compounds
Bridged Bicyclo Compounds, Heterocyclic
boron compounds
Bridged Bicyclo Compounds, Heterocyclic

---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00406
2018
false
false
false
Canada
French
drug information
drug approval
canada
administration, topical
ointments
phosphodiesterase 4 inhibitors
phosphodiesterase 4 inhibitors
child
adolescent
adult
dermatitis, atopic
treatment outcome
crisaborole
Eucrisa
crisaborole
crisaborole
boron compounds
Bridged Bicyclo Compounds, Heterocyclic
boron compounds
Bridged Bicyclo Compounds, Heterocyclic

---
Nous contacter.
18/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.